Kerecis is a biotechnology company that develops, manufactures and markets regenerative grafts from Omega3-rich fish skin. The company’s initial product (Kerecis Omega3 Wound) has been approved by the FDA and is being marketed in the U.S. and several international markets. Kerecis has in the last two years transitioned from being a research and development company into commercialization and is experiencing rapid growth and outstanding patient results.
Visit Kerecis's website at https://www.kerecis.com/careers/.
We appreciate our corporate partners. Learn more about the Corporate Partner Program.